Long-term health outcomes of chronic hepatitis C patients: A review of findings from REVEAL-HCV cohort study

Mei Hsuan Lee, Hwai I. Yang, Chien Jen Chen, C. Y. Hsieh, H. S. Lee, P. M. Yang, C. H. Chen, J. D. Chen, S. P. Huang, C. F. Jan, T. H.H. Chen, C. A. Sun, M. H. Wu, S. Y. Chen, K. E. Chu, S. C. Ho, T. G. Lu, W. P. Wu, T. Y. Ou, C. G. LinK. C. Shih, W. S. Chung, C. Li, C. C. Chen, W. C. How

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Chronic hepatitis C affects more than 180 million people worldwide. As one of the most important infectious diseases, it causes around 250,000 deaths per year. A long-term follow-up cohort study is essential for evaluating health outcomes associated with virus infection, and for exploring potential seromarkers that have high predictability for risk of developing various diseases. However, the prospective cohorts consisted of individuals with chronic hepatitis C virus (HCV) infection are still rare. The Risk Elevation of Viral Load Elevation and Associated Liver Disease/Cancer in HCV (REVEAL-HCV) study has followed a cohort of 1095 residents seropositive for anti-HCV antibodies lived in seven townships in Taiwan for 15 years. These anti-HCV seropositives were asymptomatic and relatively more healthy than chronic hepatitis C patients cared in clinics and hospitals. Most of them acquired HCV infection through iatrogenic transmission routes in study townships. The epidemiological characteristics of HCV infection were very similar to those in countries with high prevalence such as Japan, Korea, Italy, and India. As the participants in the REVEAL-HCV study rarely received antiviral therapies, it provided an exceptional opportunity to study the natural history of chronic HCV infection. In this review article, we describe the details of participant enrollment, laboratory tests, follow-up procedures, and major recent findings. Anti-HCV seropositives with elevated serum HCV RNA levels were found to have an increasing risk of developing hepatocellular carcinoma in a dose-response relationship. In addition to the serum HCV RNA level, serum alanine aminotransferase levels and HCV genotype also had long-term predictability for the risk of hepatocellular carcinoma. Moreover, anti-HCV seropositives with detectable serum HCV RNA levels had an increased mortality from extrahepatic diseases such as cerebrovascular and renal diseases. Our study revealed that anti-HCV seropositives with detectable serum HCV RNA levels had an increased risk of hepatic and extrahepatic diseases.

Original languageEnglish (US)
Pages (from-to)99-107
Number of pages9
JournalBioMedicine (Netherlands)
Volume2
Issue number3
DOIs
StatePublished - Sep 1 2012

Fingerprint

Chronic Hepatitis C
Viruses
Hepacivirus
Cohort Studies
Health
Virus Diseases
RNA
Serum
Hepatocellular Carcinoma
Satellite Viruses
Cerebrovascular Disorders
Hepatitis C Antibodies
Liver Neoplasms
Korea
Natural History
Viral Load
Alanine Transaminase
Taiwan
Italy
Antiviral Agents

Keywords

  • Extrahepatic diseases
  • Hepatic diseases
  • Prospective study
  • Serum HCV RNA

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Long-term health outcomes of chronic hepatitis C patients : A review of findings from REVEAL-HCV cohort study. / Lee, Mei Hsuan; Yang, Hwai I.; Chen, Chien Jen; Hsieh, C. Y.; Lee, H. S.; Yang, P. M.; Chen, C. H.; Chen, J. D.; Huang, S. P.; Jan, C. F.; Chen, T. H.H.; Sun, C. A.; Wu, M. H.; Chen, S. Y.; Chu, K. E.; Ho, S. C.; Lu, T. G.; Wu, W. P.; Ou, T. Y.; Lin, C. G.; Shih, K. C.; Chung, W. S.; Li, C.; Chen, C. C.; How, W. C.

In: BioMedicine (Netherlands), Vol. 2, No. 3, 01.09.2012, p. 99-107.

Research output: Contribution to journalReview article

Lee, MH, Yang, HI, Chen, CJ, Hsieh, CY, Lee, HS, Yang, PM, Chen, CH, Chen, JD, Huang, SP, Jan, CF, Chen, THH, Sun, CA, Wu, MH, Chen, SY, Chu, KE, Ho, SC, Lu, TG, Wu, WP, Ou, TY, Lin, CG, Shih, KC, Chung, WS, Li, C, Chen, CC & How, WC 2012, 'Long-term health outcomes of chronic hepatitis C patients: A review of findings from REVEAL-HCV cohort study', BioMedicine (Netherlands), vol. 2, no. 3, pp. 99-107. https://doi.org/10.1016/j.biomed.2012.06.002
Lee, Mei Hsuan ; Yang, Hwai I. ; Chen, Chien Jen ; Hsieh, C. Y. ; Lee, H. S. ; Yang, P. M. ; Chen, C. H. ; Chen, J. D. ; Huang, S. P. ; Jan, C. F. ; Chen, T. H.H. ; Sun, C. A. ; Wu, M. H. ; Chen, S. Y. ; Chu, K. E. ; Ho, S. C. ; Lu, T. G. ; Wu, W. P. ; Ou, T. Y. ; Lin, C. G. ; Shih, K. C. ; Chung, W. S. ; Li, C. ; Chen, C. C. ; How, W. C. / Long-term health outcomes of chronic hepatitis C patients : A review of findings from REVEAL-HCV cohort study. In: BioMedicine (Netherlands). 2012 ; Vol. 2, No. 3. pp. 99-107.
@article{2f539a5b02cb42809af3965219508ee0,
title = "Long-term health outcomes of chronic hepatitis C patients: A review of findings from REVEAL-HCV cohort study",
abstract = "Chronic hepatitis C affects more than 180 million people worldwide. As one of the most important infectious diseases, it causes around 250,000 deaths per year. A long-term follow-up cohort study is essential for evaluating health outcomes associated with virus infection, and for exploring potential seromarkers that have high predictability for risk of developing various diseases. However, the prospective cohorts consisted of individuals with chronic hepatitis C virus (HCV) infection are still rare. The Risk Elevation of Viral Load Elevation and Associated Liver Disease/Cancer in HCV (REVEAL-HCV) study has followed a cohort of 1095 residents seropositive for anti-HCV antibodies lived in seven townships in Taiwan for 15 years. These anti-HCV seropositives were asymptomatic and relatively more healthy than chronic hepatitis C patients cared in clinics and hospitals. Most of them acquired HCV infection through iatrogenic transmission routes in study townships. The epidemiological characteristics of HCV infection were very similar to those in countries with high prevalence such as Japan, Korea, Italy, and India. As the participants in the REVEAL-HCV study rarely received antiviral therapies, it provided an exceptional opportunity to study the natural history of chronic HCV infection. In this review article, we describe the details of participant enrollment, laboratory tests, follow-up procedures, and major recent findings. Anti-HCV seropositives with elevated serum HCV RNA levels were found to have an increasing risk of developing hepatocellular carcinoma in a dose-response relationship. In addition to the serum HCV RNA level, serum alanine aminotransferase levels and HCV genotype also had long-term predictability for the risk of hepatocellular carcinoma. Moreover, anti-HCV seropositives with detectable serum HCV RNA levels had an increased mortality from extrahepatic diseases such as cerebrovascular and renal diseases. Our study revealed that anti-HCV seropositives with detectable serum HCV RNA levels had an increased risk of hepatic and extrahepatic diseases.",
keywords = "Extrahepatic diseases, Hepatic diseases, Prospective study, Serum HCV RNA",
author = "Lee, {Mei Hsuan} and Yang, {Hwai I.} and Chen, {Chien Jen} and Hsieh, {C. Y.} and Lee, {H. S.} and Yang, {P. M.} and Chen, {C. H.} and Chen, {J. D.} and Huang, {S. P.} and Jan, {C. F.} and Chen, {T. H.H.} and Sun, {C. A.} and Wu, {M. H.} and Chen, {S. Y.} and Chu, {K. E.} and Ho, {S. C.} and Lu, {T. G.} and Wu, {W. P.} and Ou, {T. Y.} and Lin, {C. G.} and Shih, {K. C.} and Chung, {W. S.} and C. Li and Chen, {C. C.} and How, {W. C.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.biomed.2012.06.002",
language = "English (US)",
volume = "2",
pages = "99--107",
journal = "BioMedicine (Netherlands)",
issn = "2211-8020",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Long-term health outcomes of chronic hepatitis C patients

T2 - A review of findings from REVEAL-HCV cohort study

AU - Lee, Mei Hsuan

AU - Yang, Hwai I.

AU - Chen, Chien Jen

AU - Hsieh, C. Y.

AU - Lee, H. S.

AU - Yang, P. M.

AU - Chen, C. H.

AU - Chen, J. D.

AU - Huang, S. P.

AU - Jan, C. F.

AU - Chen, T. H.H.

AU - Sun, C. A.

AU - Wu, M. H.

AU - Chen, S. Y.

AU - Chu, K. E.

AU - Ho, S. C.

AU - Lu, T. G.

AU - Wu, W. P.

AU - Ou, T. Y.

AU - Lin, C. G.

AU - Shih, K. C.

AU - Chung, W. S.

AU - Li, C.

AU - Chen, C. C.

AU - How, W. C.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Chronic hepatitis C affects more than 180 million people worldwide. As one of the most important infectious diseases, it causes around 250,000 deaths per year. A long-term follow-up cohort study is essential for evaluating health outcomes associated with virus infection, and for exploring potential seromarkers that have high predictability for risk of developing various diseases. However, the prospective cohorts consisted of individuals with chronic hepatitis C virus (HCV) infection are still rare. The Risk Elevation of Viral Load Elevation and Associated Liver Disease/Cancer in HCV (REVEAL-HCV) study has followed a cohort of 1095 residents seropositive for anti-HCV antibodies lived in seven townships in Taiwan for 15 years. These anti-HCV seropositives were asymptomatic and relatively more healthy than chronic hepatitis C patients cared in clinics and hospitals. Most of them acquired HCV infection through iatrogenic transmission routes in study townships. The epidemiological characteristics of HCV infection were very similar to those in countries with high prevalence such as Japan, Korea, Italy, and India. As the participants in the REVEAL-HCV study rarely received antiviral therapies, it provided an exceptional opportunity to study the natural history of chronic HCV infection. In this review article, we describe the details of participant enrollment, laboratory tests, follow-up procedures, and major recent findings. Anti-HCV seropositives with elevated serum HCV RNA levels were found to have an increasing risk of developing hepatocellular carcinoma in a dose-response relationship. In addition to the serum HCV RNA level, serum alanine aminotransferase levels and HCV genotype also had long-term predictability for the risk of hepatocellular carcinoma. Moreover, anti-HCV seropositives with detectable serum HCV RNA levels had an increased mortality from extrahepatic diseases such as cerebrovascular and renal diseases. Our study revealed that anti-HCV seropositives with detectable serum HCV RNA levels had an increased risk of hepatic and extrahepatic diseases.

AB - Chronic hepatitis C affects more than 180 million people worldwide. As one of the most important infectious diseases, it causes around 250,000 deaths per year. A long-term follow-up cohort study is essential for evaluating health outcomes associated with virus infection, and for exploring potential seromarkers that have high predictability for risk of developing various diseases. However, the prospective cohorts consisted of individuals with chronic hepatitis C virus (HCV) infection are still rare. The Risk Elevation of Viral Load Elevation and Associated Liver Disease/Cancer in HCV (REVEAL-HCV) study has followed a cohort of 1095 residents seropositive for anti-HCV antibodies lived in seven townships in Taiwan for 15 years. These anti-HCV seropositives were asymptomatic and relatively more healthy than chronic hepatitis C patients cared in clinics and hospitals. Most of them acquired HCV infection through iatrogenic transmission routes in study townships. The epidemiological characteristics of HCV infection were very similar to those in countries with high prevalence such as Japan, Korea, Italy, and India. As the participants in the REVEAL-HCV study rarely received antiviral therapies, it provided an exceptional opportunity to study the natural history of chronic HCV infection. In this review article, we describe the details of participant enrollment, laboratory tests, follow-up procedures, and major recent findings. Anti-HCV seropositives with elevated serum HCV RNA levels were found to have an increasing risk of developing hepatocellular carcinoma in a dose-response relationship. In addition to the serum HCV RNA level, serum alanine aminotransferase levels and HCV genotype also had long-term predictability for the risk of hepatocellular carcinoma. Moreover, anti-HCV seropositives with detectable serum HCV RNA levels had an increased mortality from extrahepatic diseases such as cerebrovascular and renal diseases. Our study revealed that anti-HCV seropositives with detectable serum HCV RNA levels had an increased risk of hepatic and extrahepatic diseases.

KW - Extrahepatic diseases

KW - Hepatic diseases

KW - Prospective study

KW - Serum HCV RNA

UR - http://www.scopus.com/inward/record.url?scp=84866499776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866499776&partnerID=8YFLogxK

U2 - 10.1016/j.biomed.2012.06.002

DO - 10.1016/j.biomed.2012.06.002

M3 - Review article

AN - SCOPUS:84866499776

VL - 2

SP - 99

EP - 107

JO - BioMedicine (Netherlands)

JF - BioMedicine (Netherlands)

SN - 2211-8020

IS - 3

ER -